Regulation
News on regulation, with sources in every post. soft.report Blog.
-
FDA requires NAION warning on labels of all GLP-1 receptor agonists
The FDA now requires every GLP-1 receptor agonist, from semaglutide to tirzepatide, to carry a labeling warning about a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION).
Ophthalmology reports in your own template
The AI reads the exam, drafts the report in your template, and you review and sign. 15-day free trial, no card.
Discover soft.report